Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
Graviton BioScience
Private
Therapeutics company focused on Friedreich's Ataxia. Received IND clearance for GV101 from the FDA in August 2026.
Company Info
Upcoming Milestones & Key Dates
2026 H2
Clinical Trial
Phase 1 dosing begins for GV101